Search Results | Diabetes | American Diabetes Association

1-19 of 19

Sort by

Sort Order Select

Meeting Abstracts

346-P: Predicting True Time to Recovery from Insulin-Induced Hypoglycemia with Dasiglucagon

TADEJ BATTELINO, TIMOTHY S. BAILEY, RAMIN TEHRANCHI, LESLIE J. KLAFF, THOMAS PIEBER, ULRIKE HÖVELMANN, LEONA PLUM-MOERSCHEL, ANITA E. MELGAARD, RONNIE ARONSON, LINDA DIMEGLIO, THOMAS DANNE, ANNE L. PETERS

Diabetes 2021;70(Supplement_1):346-P

DOI: https://doi.org/10.2337/db21-346-P

Published: 01 June 2021

View article

Meeting Abstracts

37-OR: Racial and Socioeconomic Disparities in the Use of Newer Classes of Diabetes Medications

AHMED ELHUSSEIN, MICHAEL BANCKS, WILLIAM C. KNOWLER, ANNE L. PETERS, ELIZABETH M. VAUGHAN, NISA M. MARUTHUR, JEANNE CLARK, SCOTT J. PILLA

Diabetes 2020;69(Supplement_1):37-OR

DOI: https://doi.org/10.2337/db20-37-OR

Published: 01 June 2020

View article

Meeting Abstracts

655-P: Improved Outcomes with Diabetes Devices Using Lower-Literacy Teaching Guides in a Center for Underserved Individuals with Type 1 Diabetes

ANNE L. PETERS, MARTHA A. WALKER, VALERIE F. RUELAS

Diabetes 2020;69(Supplement_1):655-P

DOI: https://doi.org/10.2337/db20-655-P

Published: 01 June 2020

View article

Meeting Abstracts

1629-P: Association of Patient-Reported Outcomes (PROs) Scores with Glycemic Target Achievement in Type 1 Diabetes (T1D) in the SAGE Study

EMMA G. WILMOT, FRANCISCO JAVIER AMPUDIA BLASCO, LORI BERARD, SANDRINE BRETTE, LUIS EDUARDO P. CALLIARI, EMILY FITTS, KELLY L. CLOSE, JUAN J. GAGLIARDINO, FELIPE LAUAND, SR., ANNE L. PETERS, ERIC RENARD, AUDE ROBOREL DE CLIMENS, JOCHEN SEUFERT

Diabetes 2020;69(Supplement_1):1629-P

DOI: https://doi.org/10.2337/db20-1629-P

Published: 01 June 2020

View article

Meeting Abstracts

1626-P: Differences in Patient-Reported Outcomes (PROs) by Age and Region in Adults with Type 1 Diabetes (T1D) in the SAGE Study

LORI BERARD, FRANCISCO JAVIER AMPUDIA BLASCO, SANDRINE BRETTE, DANIELA BRUTTOMESSO, KELLY L. CLOSE, HIROSHI IKEGAMI, DUBRAVKA JURIŠIC-ERŽEN, FELIPE LAUAND, SR., ANNE L. PETERS, VALERIE PILORGET, RAMANATHAN BALAMURUGAN, ERIC RENARD, EMMA G. WILMOT, AUDE ROBOREL DE CLIMENS

Diabetes 2020;69(Supplement_1):1626-P

DOI: https://doi.org/10.2337/db20-1626-P

Published: 01 June 2020

View article

Meeting Abstracts

1102-P: Impact of Treatment with Sotagliflozin on the Incidence of Severe Hypoglycemia in Patients with T1D

JEREMY PETTUS, THOMAS DANNE, ANNE L. PETERS, AMY K. CARROLL, SANGEETA SAWHNEY, WENJUN JIANG, PHILLIP L. BANKS, JANET B. MCGILL

Diabetes 2020;69(Supplement_1):1102-P

DOI: https://doi.org/10.2337/db20-1102-P

Published: 01 June 2020

View article

Meeting Abstracts

1129-P: Effect of Sotagliflozin Added to Insulin Therapy on Beta-Hydroxybutyrate in Patients with Type 1 Diabetes

ANNE L. PETERS, THOMAS DANNE, SANGEETA SAWHNEY, PHILLIP L. BANKS, MICHAEL J. DAVIES, PABLO LAPUERTA

Diabetes 2020;69(Supplement_1):1129-P

DOI: https://doi.org/10.2337/db20-1129-P

Published: 01 June 2020

View article

Meeting Abstracts

136-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Moderate Renal Impairment

DAVID CHERNEY, ELE FERRANNINI, GUILLERMO E. UMPIERREZ, ANNE L. PETERS, JULIO ROSENSTOCK, AMY K. CARROLL, SANGEETA SAWHNEY, PHILLIP L. BANKS, WENJUN JIANG, PABLO LAPUERTA

Diabetes 2020;69(Supplement_1):136-LB

DOI: https://doi.org/10.2337/db20-136-LB

Published: 01 June 2020

View article

Meeting Abstracts

135-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Severe Renal Impairment

DAVID CHERNEY, ELE FERRANNINI, GUILLERMO E. UMPIERREZ, ANNE L. PETERS, JULIO ROSENSTOCK, AMY K. CARROLL, PABLO LAPUERTA, PHILLIP L. BANKS, WENJUN JIANG, SANGEETA SAWHNEY

Diabetes 2020;69(Supplement_1):135-LB

DOI: https://doi.org/10.2337/db20-135-LB

Published: 01 June 2020

View article

Meeting Abstracts

347-OR: The Long-Term Effects of an Intensive Lifestyle Intervention on Medicare Outcomes

PETER J. HUCKFELDT, CHRISTOPHER FRENIER, NICHOLAS M. PAJEWSKI, MARK ESPELAND, ANNE L. PETERS, RAMON CASANOVA, LAWRENCE J. CHESKIN, DANA GOLDMAN

Diabetes 2019;68(Supplement_1):347-OR

DOI: https://doi.org/10.2337/db19-347-OR

Published: 01 June 2019

View article

Meeting Abstracts

1424-P: Changes in Device Uptake and Glycemic Control among Pregnant Women with Type 1 Diabetes: Data from the T1D Exchange

CAROL J. LEVY, NICOLE C. FOSTER, STEPHANIE DUBOSE, SHIVANI AGARWAL, SARAH LYONS, ANNE L. PETERS, GABRIEL I. UWAIFO, LINDA DIMEGLIO, JENNIFER SHERR, SARIT POLSKY

Diabetes 2019;68(Supplement_1):1424-P

DOI: https://doi.org/10.2337/db19-1424-P

Published: 01 June 2019

View article

Meeting Abstracts

2418-PUB: Incident Diabetes Complications among Women with T1D Based on Parity

SARIT POLSKY, NICOLE C. FOSTER, STEPHANIE DUBOSE, SHIVANI AGARWAL, SARAH LYONS, ANNE L. PETERS, GABRIEL I. UWAIFO, LINDA DIMEGLIO, JENNIFER SHERR, CAROL J. LEVY

Diabetes 2019;68(Supplement_1):2418-PUB

DOI: https://doi.org/10.2337/db19-2418-PUB

Published: 01 June 2019

View article

Meeting Abstracts

964-P: CGM-Tele Monitoring in Older Adults with T1D: Results of a Pilot Study

MARK D. HARMEL, VALERIE F. RUELAS, EDWARD T. NYKAZA, ANNE L. PETERS

Diabetes 2019;68(Supplement_1):964-P

DOI: https://doi.org/10.2337/db19-964-P

Published: 01 June 2019

View article

Meeting Abstracts

Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2)

THOMAS DANNE, BERTRAND CARIOU, JOHN B. BUSE, SATISH K. GARG, JULIO ROSENSTOCK, PHILLIP L. BANKS, JAKE A. KUSHNER, DARREN K. MCGUIRE, ANNE L. PETERS, SANGEETA SAWHNEY, PAUL STRUMPH

Diabetes 2018;67(Supplement_1):1179-P

DOI: https://doi.org/10.2337/db18-1179-P

Published: 01 July 2018

View article

Meeting Abstracts

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (The European inTandem2 Study)

THOMAS DANNE, BERTRAND CARIOU, PHILLIP L. BANKS, MICHAEL BRANDLE, HELMUT BRATH, EDWARD FRANEK, JAKE A. KUSHNER, PABLO LAPUERTA, DARREN K. MCGUIRE, ANNE L. PETERS, SANGEETA SAWHNEY, PAUL STRUMPH

Diabetes 2018;67(Supplement_1):1122-P

DOI: https://doi.org/10.2337/db18-1122-P

Published: 01 July 2018

View article

Meeting Abstracts

Characteristics of Adult vs. Childhood-Onset Type 1 Diabetes (T1D) in the T1D Exchange Registry

ANNE L. PETERS, LAUREN KANAPKA, IRL B. HIRSCH, LORI M. LAFFEL, DANIEL J. DESALVO, SARAH LYONS, FRANCESCO VENDRAME, GRAZIA ALEPPO, LUCY D. MASTRANDREA, RICHARD E. PRATLEY, MICHAEL R. RICKELS

Diabetes 2018;67(Supplement_1):182-LB

DOI: https://doi.org/10.2337/db18-182-LB

Published: 01 July 2018

View article

Meeting Abstracts

The STEPP-UP Project—Designing Low Literacy Teaching Tools for Use of Devices in a Minority Population

VALERIE F. RUELAS, MARTHA A. WALKER, ANNE L. PETERS

Diabetes 2018;67(Supplement_1):2227-PUB

DOI: https://doi.org/10.2337/db18-2227-PUB

Published: 01 July 2018

View article

Meeting Abstracts

Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study—A Contemporary Prediabetes Cohort

ERIN LEBLANC, RICHARD E. PRATLEY, BESS DAWSON-HUGHES, MYRLENE A. STATEN, PATRICIA R. SHEEHAN, MICHAEL R. LEWIS, ANNE L. PETERS, SUN H. KIM, RANEE CHATTERJEE, VANITA ARODA, CHHAVI CHADHA, ANASTASSIOS PITTAS

Diabetes 2018;67(Supplement_1):765-P

DOI: https://doi.org/10.2337/db18-765-P

Published: 01 July 2018

View article

Meeting Abstracts

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1)

JOHN B. BUSE, SATISH K. GARG, JULIO ROSENSTOCK, TIMOTHY S. BAILEY, PHILLIP L. BANKS, BRUCE W. BODE, THOMAS DANNE, JAKE A. KUSHNER, WENDY LANE, PABLO LAPUERTA, DARREN K. MCGUIRE, ANNE L. PETERS, JOHN H. REED, SANGEETA SAWHNEY, PAUL STRUMPH

Diabetes 2018;67(Supplement_1):212-OR

DOI: https://doi.org/10.2337/db18-212-OR

Published: 01 July 2018

View article

NARROW

346-P: Predicting True Time to Recovery from Insulin-Induced Hypoglycemia with Dasiglucagon

37-OR: Racial and Socioeconomic Disparities in the Use of Newer Classes of Diabetes Medications

655-P: Improved Outcomes with Diabetes Devices Using Lower-Literacy Teaching Guides in a Center for Underserved Individuals with Type 1 Diabetes

1629-P: Association of Patient-Reported Outcomes (PROs) Scores with Glycemic Target Achievement in Type 1 Diabetes (T1D) in the SAGE Study

1626-P: Differences in Patient-Reported Outcomes (PROs) by Age and Region in Adults with Type 1 Diabetes (T1D) in the SAGE Study

1102-P: Impact of Treatment with Sotagliflozin on the Incidence of Severe Hypoglycemia in Patients with T1D

1129-P: Effect of Sotagliflozin Added to Insulin Therapy on Beta-Hydroxybutyrate in Patients with Type 1 Diabetes

136-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Moderate Renal Impairment

135-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Severe Renal Impairment

347-OR: The Long-Term Effects of an Intensive Lifestyle Intervention on Medicare Outcomes

1424-P: Changes in Device Uptake and Glycemic Control among Pregnant Women with Type 1 Diabetes: Data from the T1D Exchange

2418-PUB: Incident Diabetes Complications among Women with T1D Based on Parity

964-P: CGM-Tele Monitoring in Older Adults with T1D: Results of a Pilot Study

Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2)

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (The European inTandem2 Study)

Characteristics of Adult vs. Childhood-Onset Type 1 Diabetes (T1D) in the T1D Exchange Registry

The STEPP-UP Project—Designing Low Literacy Teaching Tools for Use of Devices in a Minority Population

Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study—A Contemporary Prediabetes Cohort

Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1)

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only